Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy

Molecular Therapy - Oncolytics - Tập 27 - Trang 224-238 - 2022
Xinyu Wu1, Sandro Matosevic1,2
1Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive RHPH 112E, West Lafayette, IN 47907, USA
2Center for Cancer Research, Purdue University, West Lafayette, IN, USA

Tài liệu tham khảo

Nersesian, 2021, NK cell infiltration is associated with improved overall survival in solid cancers: a systematic review and meta-analysis, Transl. Oncol., 14, 100930, 10.1016/j.tranon.2020.100930 Wang, 2019, NT5E/CD73 as correlative factor of patient survival and natural killer cell infiltration in glioblastoma, J. Clin. Med., 8, 1526, 10.3390/jcm8101526 Shaim, 2021, Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells, J. Clin. Invest., 131, 142116, 10.1172/JCI142116 Khaznadar, 2015, Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion, J. Immunol., 195, 2580, 10.4049/jimmunol.1500262 Choucair, 2019, Natural killer cells: a review of biology, therapeutic potential and challenges in treatment of solid tumors, Future Oncol., 15, 3053, 10.2217/fon-2019-0116 Liu, 2020, Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors, N. Engl. J. Med., 382, 545, 10.1056/NEJMoa1910607 Gonzalez, 2009, Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-α and ribavirin treatment, J. Immunol., 183, 6612, 10.4049/jimmunol.0901437 Cocker, 2021, Meta-analysis of the CD56-negative NK cell subset indicates altered functional responses and unique KIR regulation, J. Immunol., 206, 10.4049/jimmunol.206.Supp.98.21 Poli, 2009, CD56bright natural killer (NK) cells: an important NK cell subset, Immunology, 126, 458, 10.1111/j.1365-2567.2008.03027.x Björkström, 2010, CD56 negative NK cells: origin, function, and role in chronic viral disease, Trends Immunol., 31, 401, 10.1016/j.it.2010.08.003 Mehta, 2015, Cord blood as a source of natural killer cells, Front. Med., 2, 93 Dalle, 2005, Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections, Pediatr. Res., 57, 649, 10.1203/01.PDR.0000156501.55431.20 Luevano, 2012, The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation, Hum. Immunol., 73, 248, 10.1016/j.humimm.2011.12.015 Wang, 2007, High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity, Cell. Mol. Immunol., 4, 377 Goldenson, 2022, iPSC-derived natural killer cell therapies - expansion and targeting, Front. Immunol., 13, 841107, 10.3389/fimmu.2022.841107 Zeng, 2017, Generation of “off-the-shelf” natural killer cells from peripheral blood cell-derived induced pluripotent stem cells, Stem Cell Rep., 9, 1796, 10.1016/j.stemcr.2017.10.020 Woll, 2009, Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity, Blood, 113, 6094, 10.1182/blood-2008-06-165225 Fuchs, 2013, A matter of life and death: self-renewal in stem cells, EMBO Rep., 14, 39, 10.1038/embor.2012.197 Lupo, 2021, Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions, Cytotherapy, 23, 939, 10.1016/j.jcyt.2021.05.001 Knorr, 2013, Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy, Stem Cells Transl. Med., 2, 274, 10.5966/sctm.2012-0084 Bock, 2013, Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs), J. Vis. Exp., e50337 Carayol, 1998, NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions, Eur. J. Immunol., 28, 1991, 10.1002/(SICI)1521-4141(199806)28:06<1991::AID-IMMU1991>3.0.CO;2-7 Dege, 2020, Potently cytotoxic natural killer cells initially emerge from erythro-myeloid progenitors during mammalian development, Dev. Cell, 53, 229, 10.1016/j.devcel.2020.02.016 Woll, 2005, Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity, J. Immunol., 175, 5095, 10.4049/jimmunol.175.8.5095 Cichocki, 2020, iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy, Sci. Transl. Med., 12, eaaz5618, 10.1126/scitranslmed.aaz5618 Lowe, 2016, In vitro generation of human NK cells expressing chimeric antigen receptor through differentiation of gene-modified hematopoietic stem cells, Methods Mol. Biol., 1441, 241, 10.1007/978-1-4939-3684-7_20 Zhu, 2020, Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity, Blood, 135, 399, 10.1182/blood.2019000621 Zhu, 2020, Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity, Cell Stem Cell, 27, 224, 10.1016/j.stem.2020.05.008 Gong, 1994, Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells, Leukemia, 8, 652 Suck, 2005, KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity, Exp. Hematol., 33, 1160, 10.1016/j.exphem.2005.06.024 Yagita, 2000, A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation, Leukemia, 14, 922, 10.1038/sj.leu.2401769 Robertson, 1996, Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia, Exp. Hematol., 24, 406 Cheng, 2011, Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line, Cell Transpl., 20, 1731, 10.3727/096368911X580536 Harnack, 2011, Natural killer cell line YT exerts cytotoxicity against CD86+ myeloma cells, Anticancer Res., 31, 475 Jochems, 2016, An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele, Oncotarget, 7, 86359, 10.18632/oncotarget.13411 Kornbluth, 1982, Cell surface phenotype of a cloned line of human natural killer cells, J. Immunol., 129, 2831, 10.4049/jimmunol.129.6.2831 Tsuchiyama, 1998, Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection, Blood, 92, 1374, 10.1182/blood.V92.4.1374.416a33_1374_1383 Klingemann, 1996, A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood, Biol. Blood Marrow Transplant., 2, 68 Romanski, 2016, CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies, J. Cell. Mol. Med., 20, 1287, 10.1111/jcmm.12810 Wang, 2018, Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells, J. Immunother. Cancer, 6, 136, 10.1186/s40425-018-0441-8 Cao, 2021, Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer, Int. J. Biol. Sci., 17, 3850, 10.7150/ijbs.64630 Ao, 2019, Anti-αFR CAR-engineered NK-92 cells display potent cytotoxicity against αFR-positive ovarian cancer, J. Immunother., 42, 284, 10.1097/CJI.0000000000000286 Han, 2015, CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells, Sci. Rep., 5, 11483, 10.1038/srep11483 Chu, 2014, CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma, Leukemia, 28, 917, 10.1038/leu.2013.279 Tang, 2018, First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia, Am. J. Cancer Res., 8, 1083 Xu, 2019, 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies, J. Hematol. Oncol., 12, 49, 10.1186/s13045-019-0732-7 Matosevic, 2018, Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies, J. Immunol. Res., 2018, 4054815 Carlsten, 2015, Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications, Front. Immunol., 6, 266, 10.3389/fimmu.2015.00266 Portillo, 2021, Production of human CAR-NK cells with lentiviral vectors and functional assessment in vitro, STAR Protoc., 2, 100956, 10.1016/j.xpro.2021.100956 Streltsova, 2017, Retroviral gene transfer into primary human NK cells activated by IL-2 and K562 feeder cells expressing membrane-bound IL-21, J. Immunol. Methods, 450, 90, 10.1016/j.jim.2017.08.003 Gutierrez-Guerrero, 2020, Lentiviral vector pseudotypes: precious tools to improve gene modification of hematopoietic cells for research and gene therapy, Viruses, 12, 1016, 10.3390/v12091016 Nagashima, 1998, Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo, Blood, 3850, 10.1182/blood.V91.10.3850 Johnson, 2021, HIV-based lentiviral vectors: origin and sequence differences, Mol. Ther. Methods Clin. Dev., 21, 451, 10.1016/j.omtm.2021.03.018 Milone, 2018, Clinical use of lentiviral vectors, Leukemia, 32, 1529, 10.1038/s41375-018-0106-0 Sertkaya, 2021, HIV-1 sequences in lentiviral vector genomes can be substantially reduced without compromising transduction efficiency, Sci. Rep., 11, 12067, 10.1038/s41598-021-91309-w Gong, 2020, Rosuvastatin enhances VSV-G lentiviral transduction of NK cells via upregulation of the low-density lipoprotein receptor, Mol. Ther. Methods Clin. Dev., 17, 634, 10.1016/j.omtm.2020.03.017 Suerth, 2016, Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors, J. Mol. Med., 94, 83, 10.1007/s00109-015-1327-6 Suerth, 2014, Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy, Viruses, 6, 4811, 10.3390/v6124811 Suerth, 2012, Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity, Mol. Ther., 20, 1022, 10.1038/mt.2011.309 Rudek, 2021, Generation of an NFκB-driven alpharetroviral “all-in-one” vector construct as a potent tool for CAR NK cell therapy, Front. Immunol., 12, 751138, 10.3389/fimmu.2021.751138 Savan, 2010, Lentiviral gene transduction in human and mouse NK cell lines, Methods Mol. Biol., 612, 209, 10.1007/978-1-60761-362-6_14 Wang, 2021, Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells, Proc. Natl. Acad. Sci. USA, 118, 10.1073/pnas.2107507118 Bari, 2019, A distinct subset of highly proliferative and lentiviral vector (LV)-Transducible NK cells define a readily engineered subset for adoptive cellular therapy, Front. Immunol., 10, 2784, 10.3389/fimmu.2019.02784 Sinn, 2005, Gene Therapy Progress and Prospects: development of improved lentiviral and retroviral vectors – design, biosafety, and production, Gene Ther., 12, 1089, 10.1038/sj.gt.3302570 Guven, 2005, Efficient gene transfer into primary human natural killer cells by retroviral transduction, Exp. Hematol., 33, 1320, 10.1016/j.exphem.2005.07.006 Goswami, 2019, Gene therapy leaves a vicious cycle, Front. Oncol., 9, 297, 10.3389/fonc.2019.00297 Colamartino, 2019, Efficient and robust NK-cell transduction with Baboon envelope pseudotyped lentivector, Front. Immunol., 10, 2873, 10.3389/fimmu.2019.02873 Nanbakhsh, 2018, Dextran enhances the lentiviral transduction efficiency of murine and human primary NK cells, J. Vis. Exp., e55063 Allan, 2021, Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion, Mol. Ther. Methods Clin. Dev., 20, 559, 10.1016/j.omtm.2021.01.008 Robbins, 2021, Nonviral genome engineering of natural killer cells, Stem Cell Res. Ther., 12, 350, 10.1186/s13287-021-02406-6 Liu, 2020, Barriers and strategies of cationic liposomes for cancer gene therapy, Mol. Ther. Methods Clin. Dev., 18, 751, 10.1016/j.omtm.2020.07.015 Chen, 2016, Production and clinical development of nanoparticles for gene delivery, Mol. Ther. Methods Clin. Dev., 3, 16023, 10.1038/mtm.2016.23 Jang, 2012, The manipulation of natural killer cells to target tumor sites using magnetic nanoparticles, Biomaterials, 33, 5584, 10.1016/j.biomaterials.2012.04.041 Sanz-Ortega, 2019, Magnetic nanoparticles attached to the NK cell surface for tumor targeting in adoptive transfer therapies does not affect cellular effector functions, Front. Immunol., 10, 2073, 10.3389/fimmu.2019.02073 Zheng, 2019, In situ modification of the tumor cell surface with immunomodulating nanoparticles for effective suppression of tumor growth in mice, Adv. Mater., 31, 1902542, 10.1002/adma.201902542 Wu, 2018, Magnetic delivery of Fe 3 O 4 @polydopamine nanoparticle-loaded natural killer cells suggest a promising anticancer treatment, Biomater. Sci., 6, 2714, 10.1039/C8BM00588E Aronovich, 2011, The Sleeping Beauty transposon system: a non-viral vector for gene therapy, Hum. Mol. Genet., 20, R14, 10.1093/hmg/ddr140 Hackett, 2007, Integrating DNA vectors for gene therapy, Mol. Ther., 15, 10, 10.1038/sj.mt.6300065 Bexte, 2021, Non-viral sleeping beauty transposon engineered CD19-CAR-NK cells show a safe genomic integration profile and high antileukemic efficiency, Blood, 138, 2797, 10.1182/blood-2021-153999 Miller, 1997, Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer, Exp. Hematol., 25, 1140 Nagashima, 1998, Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo, Blood, 91, 3850, 10.1182/blood.V91.10.3850 Sahm, 2012, Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor, Cancer Immunol. Immunother., 61, 1451, 10.1007/s00262-012-1212-x Jiang, 2014, hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo, Immunobiology, 219, 547, 10.1016/j.imbio.2014.03.007 Imamura, 2014, Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15, Blood, 124, 1081, 10.1182/blood-2014-02-556837 Müller, 2019, High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia, Front. Immunol., 10, 3123, 10.3389/fimmu.2019.03123 Herrera, 2020, Purification, culture, and CD19-CAR lentiviral transduction of adult and umbilical cord blood NK cells, Curr. Protoc. Immunol., 131, e108, 10.1002/cpim.108 Gang, 2020, CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas, Blood, 136, 2308, 10.1182/blood.2020006619 Chu, 2015, Targeting CD20+ aggressive B-cell non-hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice, Cancer Immunol. Res., 3, 333, 10.1158/2326-6066.CIR-14-0114 Sinha, 2017, Development and evaluation of NK-CD123 CAR against high risk acute myeloid leukemia, Biol. Blood Marrow Transplant., 23, S253, 10.1016/j.bbmt.2016.12.423 Jiang, 2014, Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells, Mol. Oncol., 8, 297, 10.1016/j.molonc.2013.12.001 Oelsner, 2019, Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth, Int. J. Cancer, 145, 1935, 10.1002/ijc.32269 Chang, 2013, A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells, Cancer Res., 73, 1777, 10.1158/0008-5472.CAN-12-3558 Chambers, 2022, Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors, eLife, 11, e73699, 10.7554/eLife.73699 Binyamin, 2008, Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy, J. Immunol., 180, 6392, 10.4049/jimmunol.180.9.6392 Zhao, 2015, Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-β signaling pathway, OTT, 8, 1553 Li, 2020, CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency, J. Immunother. Cancer, 8, e000131, 10.1136/jitc-2019-000131 Ng, 2020, CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts, Mol. Ther. Oncolytics, 16, 75, 10.1016/j.omto.2019.12.006 Murakami, 2018, Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells, Anticancer Res., 38, 5049, 10.21873/anticanres.12824 Liu, 2020, Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor, Cell Prolif., 53, e12858, 10.1111/cpr.12858 Sahm, 2012, Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor, Cancer Immunol Immunother, 61, 1451, 10.1007/s00262-012-1212-x Hu, 2020, Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer, Sci. Rep., 10, 2815, 10.1038/s41598-020-59736-3 Xia, 2019, Robo1-specific CAR-NK immunotherapy enhances efficacy of 125I seed brachytherapy in an orthotopic mouse model of human pancreatic carcinoma, Anticancer Res., 39, 5919, 10.21873/anticanres.13796 2019 Da, 2022, STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer, OncoImmunology, 11, 2054105, 10.1080/2162402X.2022.2054105 Cao, 2020, Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer, Biochem. Biophys. Res. Commun., 524, 96, 10.1016/j.bbrc.2020.01.053 2019 2022 Töpfer, 2015, DAP12-Based activating chimeric antigen receptor for NK cell tumor immunotherapy, J. Immunol., 194, 3201, 10.4049/jimmunol.1400330 Schönfeld, 2015, Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor, Mol. Ther., 23, 330, 10.1038/mt.2014.219 Zhang, 2013, Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody, Immunol. Cell Biol., 91, 615, 10.1038/icb.2013.45 Wu, 2019, HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer, Bull. Cancer, 106, 946, 10.1016/j.bulcan.2019.03.012 Zhang, 2016, ErbB2/HER2-Specific NK cells for targeted therapy of glioblastoma, J. Natl. Cancer Inst., 108, 10.1093/jnci/djv375 Yu, 2018, Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma, Mol. Ther., 26, 366, 10.1016/j.ymthe.2017.12.012 Xiao, 2019, Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients, Mol. Ther., 27, 1114, 10.1016/j.ymthe.2019.03.011 MD, 2022 Liu, 2022, CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo, J. Leukoc. Biol., 112, 901, 10.1002/JLB.5MA0122-467R 2022 2022 Carlsten, 2015, Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications, Front. Immunol., 6, 266, 10.3389/fimmu.2015.00266 Huang, 2020, Enhanced NK-92 cytotoxicity by CRISPR genome engineering using Cas9 ribonucleoproteins, Front. Immunol., 11, 1008, 10.3389/fimmu.2020.01008 Hoerster, 2020, HLA class I knockout converts allogeneic primary NK cells into suitable effectors for “off-the-shelf” immunotherapy, Front. Immunol., 11, 586168, 10.3389/fimmu.2020.586168 Phatarpekar, 2016, Electroporation of siRNA to silence gene expression in primary NK cells, Methods Mol. Biol., 1441, 267, 10.1007/978-1-4939-3684-7_22 Purdy, 2010, Introduction of shRNAs into human NK-like cell lines with retrovirus, Methods Mol. Biol., 612, 223, 10.1007/978-1-60761-362-6_15 Figueiredo, 2009, Permanent silencing of NKG2A expression for cell-based therapeutics, J. Mol. Med., 87, 199, 10.1007/s00109-008-0417-0 Nguyen, 2020, Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency, Nat. Biotechnol., 38, 44, 10.1038/s41587-019-0325-6 Lu, 2021, From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies, Front. Oncol., 11 Klingemann, 2014, Are natural killer cells superior CAR drivers?, OncoImmunology, 3, e28147, 10.4161/onci.28147 Liu, 2021, NK cell-based cancer immunotherapy: from basic biology to clinical development, J. Hematol. Oncol., 14, 7, 10.1186/s13045-020-01014-w Romee, 2014, Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer, Scientifica, 2014, e205796, 10.1155/2014/205796 Lupo, 2019, Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy, Cancers, 11, 769, 10.3390/cancers11060769 Sutlu, 2012, Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy, Hum. Gene Ther., 23, 1090, 10.1089/hum.2012.080 Irving, 2021, Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells, Hum. Gene Ther., 32, 1044, 10.1089/hum.2021.173 Veluchamy, 2017, The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments, Front. Immunol., 8, 631, 10.3389/fimmu.2017.00631 Simonetta, 2017, Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation, Front. Immunol., 8, 465, 10.3389/fimmu.2017.00465 Albinger, 2021, Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany, Gene Ther., 28, 513, 10.1038/s41434-021-00246-w Mizia-Malarz, 2019, NK cells as possible prognostic factor in childhood acute lymphoblastic leukemia, Dis. Markers, 2019, e3596983, 10.1155/2019/3596983 Gong, 2021, Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy, J. Hematol. Oncol., 14, 73, 10.1186/s13045-021-01083-5 Christodoulou, 2021, Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities, J. Immunother. Cancer, 9, e003894, 10.1136/jitc-2021-003894 Chu, 2015, Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells in Vitro and in NSG Mice, Cancer Immunol. Res., 3, 333, 10.1158/2326-6066.CIR-14-0114 Release Marofi, 2021, CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies, Stem Cell Res. Ther., 12, 374, 10.1186/s13287-021-02462-y Jiang, 2014, Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells, Mol. Oncol., 8, 297, 10.1016/j.molonc.2013.12.001 Leivas, 2021, NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma, Blood Cancer J., 11, 146, 10.1038/s41408-021-00537-w Reiser, 2021, Dual chimeric antigen receptor approach combining novel tumor targeting strategies circumvents antigen escape in multiple myeloma, Blood, 138, 1718, 10.1182/blood-2021-154025 Wrona, 2021, CAR-NK cells in the treatment of solid tumors, Int. J. Mol. Sci., 22, 5899, 10.3390/ijms22115899 Condamine, 2016, Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients, Sci. Immunol., 1, aaf8943, 10.1126/sciimmunol.aaf8943 Lee, 2021, Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells, J. Immunother. Cancer, 9, e002128, 10.1136/jitc-2020-002128 Zhang, 2020, Equipping natural killer cells with specific targeting and checkpoint blocking aptamers for enhanced adoptive immunotherapy in solid tumors, Angew. Chem. Int. Ed. Engl., 132, 12120, 10.1002/ange.202002145 Lu, 2020, A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis, Mol. Immunol., 122, 200, 10.1016/j.molimm.2020.04.016 Zhang, 2018, Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models, J. Immunol. Res., 2018, e4263520 Chen, 2016, A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases, Oncotarget, 7, 27764, 10.18632/oncotarget.8526 Yao, 2021, Chemokine networks modulating natural killer cell trafficking to solid tumors, Cytokine Growth Factor Rev., 59, 36, 10.1016/j.cytogfr.2020.12.003 Xie, 2020, CAR-NK cells: a promising cellular immunotherapy for cancer, EBioMedicine, 59, 102975, 10.1016/j.ebiom.2020.102975 Kang, 2021, The advances and challenges of NK cell-based cancer immunotherapy, Curr. Oncol., 28, 1077, 10.3390/curroncol28020105 Rezvani, 2017, Engineering natural killer cells for cancer immunotherapy, Mol. Ther., 25, 1769, 10.1016/j.ymthe.2017.06.012 Bi, 2017, NK cell exhaustion, Front. Immunol., 8, 760, 10.3389/fimmu.2017.00760 Chambers, 2018, Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells, Front. Immunol., 9, 2517, 10.3389/fimmu.2018.02517 Brand, 2016, LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells, Cell Metabol., 24, 657, 10.1016/j.cmet.2016.08.011 Chambers, 2019, Immunometabolic dysfunction of natural killer cells mediated by the hypoxia-CD73 axis in solid tumors, Front. Mol. Biosci., 6, 60, 10.3389/fmolb.2019.00060 Chambers, 2018, Adenosinergic signaling alters natural killer cell functional responses, Front. Immunol., 9, 2533, 10.3389/fimmu.2018.02533 Domagala, 2020, The tumor microenvironment—a metabolic obstacle to NK cells’ activity, Cancers (Basel), 12, 3542, 10.3390/cancers12123542 Sun, 2017, High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer, OncoImmunology, 6, e1264562, 10.1080/2162402X.2016.1264562 Niu, 2020, PD-1-positive natural killer cells have a weaker antitumor function than that of PD-1-negative natural killer cells in lung cancer, Int. J. Med. Sci., 17, 1964, 10.7150/ijms.47701 Judge, 2020, Characterizing the dysfunctional NK cell: assessing the clinical relevance of exhaustion, anergy, and senescence, Front. Cell. Infect. Microbiol., 10, 49, 10.3389/fcimb.2020.00049 Tran, 2017, TGFβR1 blockade with galunisertib (LY2157299) enhances anti-neuroblastoma activity of the anti-GD2 antibody dinutuximab (ch14.18) with natural killer cells, Clin. Cancer Res., 23, 804, 10.1158/1078-0432.CCR-16-1743 Peled, 2017, Enhanced in vivo persistence and proliferation of NK cells expanded in culture with the small molecule nicotinamide: development of a clinical-applicable method for NK expansion, Blood, 130, 657, 10.1182/blood.V130.Suppl_1.657.657 Felices, 2016, Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells, Methods Mol. Biol., 1441, 333, 10.1007/978-1-4939-3684-7_28 Gleason, 2014, CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets, Blood, 123, 3016, 10.1182/blood-2013-10-533398 Schmohl, 2017, Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity, Cancer Res. Treat., 49, 1140, 10.4143/crt.2016.491 Felices, 2019, Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL, Blood Adv., 3, 897, 10.1182/bloodadvances.2018029371 Abdolahi, 2021, Adaptive NK cell therapy modulated by anti-PD-1 antibody in gastric cancer model, Front. Pharmacol., 12, 733075, 10.3389/fphar.2021.733075 Yao, 2021, Chemokine networks modulating natural killer cell trafficking to solid tumors, Cytokine Growth Factor Rev., 59, 36, 10.1016/j.cytogfr.2020.12.003 Liu, 2018, Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity, Leukemia, 32, 520, 10.1038/leu.2017.226 Jamali, 2020, Highly efficient generation of transgenically augmented CAR NK cells overexpressing CXCR4, Front. Immunol., 11, 2028, 10.3389/fimmu.2020.02028 Li, 2022, KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape, Nat. Med., 28, 2133, 10.1038/s41591-022-02003-x Strassheimer, 2020, P06.12 Combination therapy of CAR-NK-cells and anti-PD-1 antibody results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo, J. Immunother. Cancer, 8